ROIV Roivant Sciences Ltd. Common Shares

XNAS 35.72 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ROIV $35.72 —
Key stats
$35.72
Pre-market $35.72 +0.00%
52-Week Range
$15.25 – $42.50
YTD
+62.88%
IV Rank (30D)
50.43
Straddle Price
$2.83
P/C Vol Ratio
0.30
Market Cap
$25.8B
Fair Value
MODEL: SHORT

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.29%
Beta vs SPY0.90
Cost of Equity (CAPM)9.78% (VRP-adj)
WACC9.64%
Volatility Risk Premium+38.1pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-8.2%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.8B
Return on Equity (TTM)-6.3%
Book / Price19.7%
Gross Margin (TTM)100.0%
FCF Margin (TTM)-10901.0%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$36.59 (Market Anchor value)
SMA 20 / Bollinger Mid$38.35
Bollinger Width / SMA2060.4% (drives anchor stability)
Net Debt$-1.2B
Market Cap$25B
Peers used for multiples: ARWR, BTSG, GH, NTRA, PRAX, RVMD, TERN, UTHR
60-Day Conviction
79%
20-Day Fair Value
≈ by Nov 3, 2026
$35.96
α +0.7% rank 26%
conviction
49%
40-Day Fair Value
≈ by Dec 2, 2026
$35.70
α -0.0% rank 26%
conviction
1%
60-Day Fair Value
≈ by Dec 31, 2026
$34.72
α -2.8% rank 26%
conviction
79%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $42.87 22% median 6.1× · 7 peers
Peer P/S $0.15 22% median 13.7× · 5 peers
Market Anchor (SMA50) $36.59 0% stability 0% (BB-width)
Options Expected (B-L 30d) $36.13 56% 31 strikes · skew +0.44
As of 2026-10-05 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$25.8B

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -9.86% 5
Feb +7.04% 5
Mar -7.57% 5
Apr +2.84% 5
May +2.80% 5
Jun +5.25% 5
Jul +4.19% 5
Aug +0.51% 5
Sep +4.98% 5
Oct +4.81% 6
Nov +2.39% 5
Dec +18.71% 5
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $38.35
SMA 50: $36.59
SMA 200: $30.18
Current: $35.72
EMA 12: $36.90
EMA 26: $37.17
MACD: -0.2692 | Signal: -0.4662
BULLISH
ADX (14): 15.79
RANGE
+DI: 21.35
−DI: 27.73

Momentum Oscillators

RSI (14): 42.13
NEUTRAL
Stoch %K: 10.69
Stoch %D: 15.17
Williams %R: -91.09

Volume & Volatility

BB Upper: $42.79
BB Lower: $33.91
NEUTRAL
OBV: 307,803,803
Vol SMA 20: 8,787,650
Vol ROC: -86.36%
ATR: $1.35
True Range: $0.81
HV 20: 69.6%
HV 30: 61.7%
HV 60: 49.7%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-04T00:00:00 – 2026-10-02T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary

Overall Assessment: BULLISH (Confidence Level: 7/10)

Key Drivers and Primary Risks:

  • Strong technical signals, including a bullish MACD crossover and rising RSI
  • Positive news sentiment, driven by developments in the myasthenia gravis market and Priovant's expansion of its brepocitinib development program
  • Above-average volatility, potentially amplifying price movements

Investment Thesis:

ROIV has strong technical momentum, driven by a series of positive news headlines. The stock is trading above its short-term moving averages and showing signs of consolidation. While there are some risks present, such as high volatility and potential market corrections, the overall sentiment remains bullish.

Recent News Sentiment Impact: Positive news sentiment has had a significant impact on ROIV's price movement, driving it higher over the past few weeks.

Technical Analysis

Trend Direction:

  • Short-term (1-4 weeks): Uptrend
  • Medium-term (1-3 months): Bullish momentum
  • Long-term (3-12 months): Consolidation with an uptrend bias

Support/Resistance Levels:

  • SMA 20: $34.49
  • SMA 50: $32.98
  • Upper Bollinger Band: $35.81

Momentum Signals:

  • RSI interpretation: Neutral (59.76)
  • MACD signal: Bullish
  • Bollinger Bands position: Squeeze

Volume Analysis: Volume is trading within a moderate range, with no clear trends or patterns.

News & Sentiment Analysis

Recent Headlines Summary:

The past few weeks have seen a string of positive news headlines, including developments in the myasthenia gravis market and Priovant's expansion of its brepocitinib development program. These headlines have driven a strong uptrend in ROIV's price.

Sentiment Assessment: Positive sentiment has dominated, with an overall sentiment score of 0.85 (out of 1).

Catalyst Identification:

  • Upcoming events: Priovant's Phase 2b/3 trial results and the expansion of brepocitinib development program
  • Regulatory changes: FDA approvals for myasthenia gravis treatments

Risk & Volatility Assessment

Beta Interpretation: ROIV has a beta of 1.07, indicating above-average volatility relative to the market.

Volatility Regime: Current volatility is higher than historical levels.

Options Market Signals:

  • IV rank: Low (8.5%)
  • Put/call ratio: Neutral (0.86)

Downside Protection: Support levels include SMA 20 and SMA 50, with potential for further upside if these levels are broken.

Market Context & Positioning

Sector Performance: ROIV is outperforming the broader market sector.

Institutional Activity: Institutional interest is moderate to high, based on volume patterns and options activity.

Correlation Analysis: ROIV has a relatively low correlation with the market (R-squared = 0.32).

Relative Valuation: ROIV is trading within its historical range, with no clear signs of overvaluation or undervaluation.

Key Levels & Action Items

Critical Price Levels:

  • SMA 20: $34.49
  • Upper Bollinger Band: $35.81

Breakout/Breakdown Levels:

  • SMA 50: $32.98 (potential support level)
  • Lower Bollinger Band: $33.18 (potential resistance level)

Time-Sensitive Catalysts: Priovant's Phase 2b/3 trial results and the expansion of brepocitinib development program.

Risk Management: Stop-loss levels should be set at SMA 20, with position sizing considerations based on the stock's volatility and market conditions.

Generated
Earnings History
8 of 8 under expected move
Avg Expected Move
7.21%
Avg Actual Move
3.33%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-12 After-Close 3.78% 0.93% 0.25x Within
2025-02-10 Pre-Market 6.24% 0.74% 0.12x Within
2025-05-29 Pre-Market 7.77% 6.40% 0.82x Within
2025-08-11 After-Close 3.80% 3.58% 0.94x Within
2025-11-10 Pre-Market 7.76% 0.68% 0.09x Within
2026-02-06 After-Close 8.89% 6.99% 0.79x Within
2026-05-20 After-Close 9.85% 4.96% 0.50x Within
2026-08-06 After-Close 9.58% 2.35% 0.25x Within

ROIV Options Activity & IV Rank

ROIV IV rank history, 52-week IV rank and IV percentile →

IV Rank (30D)
50.43
IV Rank (7D)
23.86
IV (30D ATM)
52.7%
Straddle (30D)
$2.83
Straddle (7D)
$2.83
P/C Volume
0.30
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.98
Correlation (SPY)
27.5%
R²
0.08
Ann. Volatility
46.4%
SPY Volatility
13.0%

Moderate volatility - stock generally follows market

Beta & Alpha Over Time

ROIV Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 698,112,204 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

518 filers605,848,907 shares$20.82B value86.78% of float
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 81,020,390 $2.87B 13.77% 11.61% 2026-06-30
2 BlackRock, Inc. Custodian 48,236,091 $1.71B 8.20% 6.91% 2026-06-30
3 Morgan Stanley Custodian 42,592,905 $1.51B 7.24% 6.10% 2026-06-30
4 Vanguard Group Inc Custodian 42,059,041 $912.68M 4.38% 6.02% 2025-12-31
5 QVT Financial LP 23,723,074 $839.56M 4.03% 3.40% 2026-06-30
6 Vanguard Capital Management LLC 22,123,198 $782.94M 3.76% 3.17% 2026-06-30
7 Vanguard Portfolio Management LLC 21,641,339 $765.89M 3.68% 3.10% 2026-06-30
8 Goldman Sachs Group Inc Custodian 18,556,458 $656.71M 3.15% 2.66% 2026-06-30
9 State Street Corp 17,795,975 $629.80M 3.02% 2.55% 2026-06-30
10 UBS Group AG Custodian 17,466,641 $618.14M 2.97% 2.50% 2026-06-30
11 FARALLON CAPITAL MANAGEMENT, L.L.C. 14,309,000 $506.40M 2.43% 2.05% 2026-06-30
12 Geode Capital Management, LLC Custodian 11,674,380 $425.54M 2.04% 1.67% 2026-06-30
13 ADAGE CAPITAL PARTNERS GP, L.L.C. 10,349,328 $366.26M 1.76% 1.48% 2026-06-30
14 Two Seas Capital LP 8,475,356 $299.94M 1.44% 1.21% 2026-06-30
15 Assenagon Asset Management S.A. 8,362,952 $295.96M 1.42% 1.20% 2026-06-30
16 PERCEPTIVE ADVISORS LLC 8,085,461 $286.14M 1.37% 1.16% 2026-06-30
17 Patient Square Capital LP 8,020,928 $283.86M 1.36% 1.15% 2026-06-30
18 Invesco Ltd. Custodian 7,531,192 $266.53M 1.28% 1.08% 2026-06-30
19 Darwin Global Management, Ltd. 6,747,300 $234.33M 1.13% 0.97% 2026-06-30
20 AQR Capital Management, LLC Custodian 6,633,560 $234.03M 1.12% 0.95% 2026-06-30
21 VIKING GLOBAL INVESTORS LP 6,271,467 $221.95M 1.07% 0.90% 2026-06-30
22 Rubric Capital Management LP 6,000,000 $212.34M 1.02% 0.86% 2026-06-30
23 Citadel Advisors LLC Custodian 5,576,261 $197.34M 0.95% 0.80% 2026-06-30
24 Dimensional Fund Advisors LP Custodian 5,230,417 $185.06M 0.89% 0.75% 2026-06-30
25 T. Rowe Price Associates, Inc. 4,816,741 $170.47M 0.82% 0.69% 2026-06-30
14 filers$358.59M notional
# Filer Notional Value % of Total Period
1 Jane Street Group, LLC Custodian $257.83M 71.90% 2026-06-30
2 Two Seas Capital LP $52.47M 14.63% 2026-06-30
3 Susquehanna International Group, LLP Custodian $18.19M 5.07% 2026-06-30
4 Caption Management, LLC $10.79M 3.01% 2026-06-30
5 Citadel Advisors LLC Custodian $4.82M 1.35% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $3.89M 1.09% 2026-06-30
7 IMC-Chicago, LLC Custodian $3.63M 1.01% 2026-06-30
8 TUDOR INVESTMENT CORP ET AL $2.72M 0.76% 2026-06-30
9 Wolverine Trading, LLC Custodian $1.17M 0.33% 2025-09-30
10 Citigroup Inc. Custodian $955.53K 0.27% 2026-06-30
11 Simplex Trading, LLC Custodian $944.91K 0.26% 2026-06-30
12 BNP Paribas Financial Markets Custodian $601.63K 0.17% 2026-06-30
13 Point72 Asset Management, L.P. $555.62K 0.15% 2026-06-30
14 Walleye Capital LLC $14.16K <0.01% 2026-06-30
13 filers$373.09M notional
# Filer Notional Value % of Total Period
1 Wells Fargo & Company Custodian $339.74M 91.06% 2026-06-30
2 Susquehanna International Group, LLP Custodian $14.05M 3.76% 2026-06-30
3 Jane Street Group, LLC Custodian $4.13M 1.11% 2026-06-30
4 Citadel Advisors LLC Custodian $3.56M 0.95% 2026-06-30
5 Simplex Trading, LLC Custodian $3.41M 0.91% 2026-06-30
6 GROUP ONE TRADING LLC Custodian $2.87M 0.77% 2026-06-30
7 IMC-Chicago, LLC Custodian $1.65M 0.44% 2026-06-30
8 Caption Management, LLC $1.06M 0.28% 2026-06-30
9 Citigroup Inc. Custodian $955.53K 0.26% 2026-06-30
10 Wolverine Trading, LLC Custodian $748.96K 0.20% 2025-09-30
11 TUDOR INVESTMENT CORP ET AL $647.64K 0.17% 2026-06-30
12 Point72 Asset Management, L.P. $233.57K 0.06% 2026-06-30
13 STEMPOINT CAPITAL LP $40.00K 0.01% 2026-06-30

ROIV Insider Trading (Form 4)

Latest: 2026-10-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-02 Frank Torti President and Vant Chair Tax (F) +40,309 $36.57 $1.47M EDGAR
2026-10-02 Mayukh Sukhatme President & CIO Tax (F) −46,879 $36.57 -$1.71M EDGAR
2026-10-02 Matthew Gline CEO Tax (F) −76,171 $36.57 -$2.79M EDGAR
2026-10-02 Eric Venker President & Immunovant CEO Mixed — $20.23 -$6.55M EDGAR
2026-09-22 Richard Pulik CFO Tax (F) −2,129 $39.77 -$84.7K EDGAR
2026-09-22 Jennifer Humes Chief Accounting Officer Tax (F) −3,880 $39.77 -$154.3K EDGAR
2026-09-18 Meghan Fitzgerald Director Award (A) +5,054 — EDGAR
2026-09-18 Daniel Allen Gold Director Award (A) +5,054 — EDGAR
2026-09-18 James C Momtazee Director Award (A) +5,054 — EDGAR
2026-09-18 Ilan Oren Director Award (A) +5,054 — EDGAR
2026-09-18 Keith S Manchester Director Award (A) +5,054 — EDGAR
2026-09-18 Epperly Melissa B, Director Award (A) +5,054 — EDGAR
2026-09-17 Meghan Fitzgerald Director Sell (S) −5,112 $39.74 -$203.2K EDGAR
2026-09-17 Epperly Melissa B, Director Sell (S) −4,938 $39.74 -$196.2K EDGAR
2026-09-14 Meghan Fitzgerald Director Tax (F) −1,743 $40.94 -$71.4K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ROIV Insider Holdings

15 insiders · @ $35.72
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Vivek Ramaswamy 10%+ Owner 47,011,612 $1.68B -$193.16M 10 2025-12-15
2 Daniel Allen Gold Director 24,468,928 $874.03M -$265.35M 13 2026-09-18
3 Mayukh Sukhatme President & CIO 20,241,558 $723.03M -$124.75M 16 2026-10-02
4 Keith S Manchester Director 16,880,786 $602.98M -$183.55M 11 2026-09-18
5 Matthew Gline CEO 16,583,774 $592.37M -$69.51M 31 2026-10-02
6 QVT Financial LP 15,928,113 $568.95M -$224.47M 7 2026-02-13
7 Frank Torti President and Vant Chair 13,495,893 $482.07M -$82.04M 6 2026-10-02
8 Eric Venker President & Immunovant CEO 1,599,154 $57.12M -$184.40M 53 2026-10-02
9 Richard Pulik CFO 269,681 $9.63M -$9.12M 46 2026-09-22
10 Rakhi Kumar Chief Accounting Officer 162,306 $5.80M -$6.58M 24 2025-02-24
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ROIV Proposed Insider Sales (Form 144)

Latest: 2026-09-30
Last 30d: 4 filings · $9.2M notice value  ·  Last 90d: 12 filings · $59.8M notice value · 4 unique filers · 50% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: MAYUKH SUKHATME (6, $36.5M) · Venker Eric (3, $21.5M) · MELISSA EPPERLY (1, $931K) · MEGHAN FITZGERALD (2, $908K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-09-30 Venker Eric Officer 200,000 $7.32M 2026-09-30 Rockefeller Financial LLC 10b5-1 EDGAR
2026-09-15 MELISSA EPPERLY Director 22,688 $930.7K 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-15 MEGHAN FITZGERALD Officer 5,112 $209.7K 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-08 MEGHAN FITZGERALD Director 20,000 $698.6K 2026-09-08 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-28 Venker Eric Officer 200,000 $7.15M 2026-08-28 Rockefeller Financial LLC 10b5-1 EDGAR
2026-08-21 MAYUKH SUKHATME Officer, Director 144,756 $5.28M 2026-08-21 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-20 MAYUKH SUKHATME Officer, Director 17,519 $653.4K 2026-08-20 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-19 MAYUKH SUKHATME Officer, Director 172,899 $6.43M 2026-08-19 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-18 MAYUKH SUKHATME Officer, Director 136,942 $5.03M 2026-08-18 Morgan Stanley Smith Barney LLC … — EDGAR
2026-08-17 MAYUKH SUKHATME Officer, Director 284,707 $10.32M 2026-08-17 Morgan Stanley Smith Barney LLC … — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
Recent SEC Filings
Latest: 2026-05-20
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-05-20 0001635088-26-000060 EDGAR
2026-04-02 0001140361-26-012885 EDGAR
2026-03-03 0001140361-26-007447 EDGAR
2026-03-03 0001140361-26-007548 EDGAR
2026-02-06 0001635088-26-000009 EDGAR
2025-12-11 0001140361-25-045204 EDGAR
2025-11-10 0001140361-25-041269 EDGAR
2025-09-17 0001140361-25-035190 EDGAR
2025-09-11 0001140361-25-034711 EDGAR
2025-09-03 0001140361-25-033767 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-05-20 0001635088-26-000061 EDGAR
2025-05-29 0001140361-25-020715 EDGAR
2024-05-30 0001140361-24-028145 EDGAR
2023-06-28 0001140361-23-031798 EDGAR
2022-06-28 0001193125-22-183362 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-02-06 0001635088-26-000011 EDGAR
2025-11-10 0001635088-25-000016 EDGAR
2025-08-11 0001140361-25-030001 EDGAR
2025-02-10 0001140361-25-003661 EDGAR
2024-11-12 0001140361-24-046019 EDGAR
2024-08-09 0001140361-24-036642 EDGAR
2024-02-13 0001140361-24-007260 EDGAR
2023-11-13 0001140361-23-052721 EDGAR
2023-08-14 0001140361-23-039406 EDGAR
2023-02-13 0001140361-23-006180 EDGAR
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio6.1
P/S Ratio3404.5
EV/EBITDA-17.9
TTM Revenue$0.0B
TTM Net Income$-0.3B
TTM EPS$-0.47
ROE-6.3%